Premier Perspectives The blog for insider insights in clinical development Clinical Research: Phase 1 - Phase 4 Leveraging Technology and Expert Clinician Review to Enhance Risk Detection in Neuroscience Studies By Andreas Schreiner October 16, 2023 Featured Posts Clinical ResearchPhase 1 - Phase 4 5 Key Takeaways: Insights on Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies By Andreas Schreiner April 8, 2021 Consulting Parkinson’s: Why Has Disease Modification Failed — and What Now? By Andreas Schreiner December 19, 2018 Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseLife at Premier By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Clinical ResearchPhase 1 - Phase 4 Finding the Path to Disease Modification in Parkinson’s Disease By Andreas Schreiner November 29, 2018 New Research Highlights the Challenges of Studying Alzheimer’s Disease By Andreas Schreiner October 30, 2018 Clinical ResearchPhase 1 - Phase 4 Making the Case for Long-acting Antipsychotic Treatment By Andreas Schreiner September 11, 2018 × ALSO OF INTERESTOutsourcing-Pharma – Trials suggest...Outsourcing-Pharma – Clinical trial logistics...Designing Pediatric Analgesic Treatment...
